Interaction between non-psychotropic cannabinoids in marihuana: Effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews

Psychopharmacology

Volumn 215, Issue 3, 2011, Pages 505-512

  Rock, Erin M ^a   Goodwin, Jennifer M ^a   Limebeer, Cheryl L ^a   Breuer, Aviva ^b   Pertwee, Roger G ^c   Mechoulam, Raphael ^a   Parker, Linda A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

5 HT1A; Cannabidiol; Cannabigerol; Cannabinoids; Nausea; Phytocannabinoid; Serotonin; Vomiting

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CANNABIDIOL; CANNABIGEROL; CANNABIS; ANTIEMETIC AGENT; CANNABINOID; SACCHARIN; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ANTINAUSEA EFFECT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RAT; VOMITING; ANIMAL; AVOIDANCE BEHAVIOR; CHEMISTRY; DRUG INTERACTION; ISOLATION AND PURIFICATION; SHREW; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIEMETICS; AVOIDANCE LEARNING; CANNABIDIOL; CANNABINOIDS; CANNABIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SACCHARIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SHREWS;

EID: 80052341043     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2157-4     Document Type: Article

References (43)

1. Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56: 2097-2102
2. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Starvi M et al (2008) Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod 71: 1427-1430
3. Breslin PAS, Grill HJ, Spector AC (1992) A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci 106: 820-836
4. Cascio MG, Gauson LA, Ross RA, Pertwee RG (2010) Evidence that the plant cannabionoid cannabigerol is a highly potent α2- adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159: 129-141
5. Colasanti BK (1990) A comparison of the ocular and central effects of delta-9-tetrahydrocannabinol and cannabigerol. J Ocular Pharmacol Ther 6: 259-269
6. Colasanti BK, Craig CR, Allara RD (1984) Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol and cannabigerol. Exper Eye Res 39: 251-259 (Pubitemid 15158975)
7. Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharmacol Biochem Behav 69: 239-249 (Pubitemid 32566269)
8. Darmani NA, Janoyan JJ, Crim J, Ramirez J (2007) Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol 563: 187-196 (Pubitemid 46602236)
9. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and malastatin type-8. J Pharmacol Exp Ther 325: 1007-1015 (Pubitemid 351724325)
10. Eisohly HN, Turner CE, Clark AM, Eisohly MA (2006) Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharm Sci 71: 1319-1323
11. Gaoni Y, Mechoulam R (1964a) Isolation, structure, and partial synthesis of an active component of hashish. J Amer Chem Soc 86: 1646-1647
12. Gaoni Y, Mechoulam R (1964b) The structure and synthesis of cannabigerol, a new hashish constituent. Proc Chem Soc 82
13. Grill HC, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143: 263-279 (Pubitemid 8277909)
14. Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H et al (2004) Cannabidiol prevents infarction via the non- CB1 cannabinoid receptor mechanism. NeuroReport 15: 2381-2385 (Pubitemid 39488924)
15. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacol 174: 254-259 (Pubitemid 38916299)
16. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387 (Pubitemid 44268348)
17. Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. NeuroReport 10: 3769-3772 (Pubitemid 30005439)
18. Limebeer CL, Parker LA (2003) The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacol 166: 120-126 (Pubitemid 36313118)
19. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA (2010) Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharm (in press)
20. Lucot JB, Crampton GH (1988) 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin, or xylazine. Pharmacol Biochem Behav 33: 627-632
21. Maor Y, Morowitz M, Gallily R, Mechoulam R (2005) Cannabigerol-dimethyl heptyl (CBG-DMH), a synthetic cannabinoid with hypotensive and vasorelaxant properties. Presented at the symposium of the International Cannabinoid Research Society, Clearwater, FL, June
22. Mechoulam R (1970) Marihuana chemistry. Science 168: 1159-1163
23. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S-19S Mechoulam R, Peters M, Murillo-Rodriquez E, Hanus LO (2007) Cannabidiol-recent advances. Chem Biodiv 4: 1678-1692 (Pubitemid 35205041)
24. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010) Potency trends of Δ9- THC and other cannabinoids in confiscated cannabis preparations from 1993-2008. J Forensic Sci 55: 1209-1217
25. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K et al (2005) Cannabidiol prevents infarction via a serotonergic 5- hydroxytryptamine1A receptor-dependent mechanism. Stroke 36: 1071-1076 (Pubitemid 40629305)
26. Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140: 1431-1433 (Pubitemid 10024954)
27. Parker LA, Limebeer CL (2008) Cannabinoids and the management of nausea and vomiting. In: Kofalvi A (ed) Cannabinoids and the brain. Springer, New York
28. Parker LA, Mechoulam R (2003) Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Phsyiol Behav Sci 38: 133-145 (Pubitemid 37195214)
29. Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a nonpsychoactive component of cannabis, and its dimethylheptyl homolog suppress nausea in an experimental model with rats. NeuroReport 13: 567-570 (Pubitemid 34293468)
30. Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P (2003) Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacol 166: 156-162 (Pubitemid 36313122)
31. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacol 171: 156-161 (Pubitemid 38134652)
32. Parker LA, Limebeer CL, Kwiatkowska M (2005) Cannabinoids: effects on vomiting and nausea in animal models. In: Mechoulam R (ed) Cannabinoids as therapeutics. Birkhäuser, Switzerland, pp 183-200
33. Parker LA, Kwiatkowska M, Mechoulam R (2006) Delta-9- tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87: 61-71
34. Parker LA, Limebeer CL, Rana SA (2008) Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62: 189-209
35. Parker, LA., Limebeer CL, Rock EM, Litt DL, Kwiatkowska M., and Piomelli D. (2009) The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine- induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97: 121-124
36. Pertwee RG (2004) In: DiMarzo V (ed) The pharmacology and therapeutic potential of cannabidiol, in cannabinoids. Kluwer, New York
37. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacol 196: 389-395
38. Rock EM, Limebeer CL, Fletcher PJ, Mechoulam R, Parker LA (2010). Cannabidiol (the non-psychoactive component of cannabis) may act as a 5-HT1A auto-receptor agonist to reduce toxininduced nausea and vomiting. Poster presented at the Society for Neuroscience meeting, San Diego, CA
39. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res 30: 1037-1043 (Pubitemid 41570039)
40. Sallan SE, Zinberg NE, Frei E (1975) Antiemetic effect of delta-9- tetrahydrocannabinol in patients receiving cancer chemotherapy. New Engl J Med 293: 795-797
41. Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323: 1-8
42. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS et al (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterol 121: 767-774 (Pubitemid 32959386)
43. Wilkinson JD, Williamson EM (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45: 87-92 (Pubitemid 46108487)